SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-55174"
 

Search: onr:"swepub:oai:DiVA.org:uu-55174" > Pleural disease dur...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003194naa a2200385 4500
001oai:DiVA.org:uu-55174
003SwePub
008081017s1997 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1955275
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-551742 URI
024a https://doi.org/10.1183/09031936.97.101227112 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:19552752 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Hillerdal, Gunnaru Karolinska Institutet4 aut
2451 0a Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos
264 c 1997-12-01
264 1b European Respiratory Society (ERS),c 1997
338 a print2 rdacarrier
520 a Bromocriptine, which is used in the treatment of Parkinson's disease, can cause adverse pleuropulmonary reactions. Exposure to asbestos can result in similar lesions. Fifteen patients with former exposure to asbestos, who developed pleural fibrosis after treatment with bromocriptine, were observed independently in Sweden (11 patients) and Australia (four patients). The patients complained of malaise, often associated with weight loss, dyspnoea, and a disturbing cough. Laboratory values included increased erythrocyte sedimentation rate and a low haemoglobin level. Lung function tests showed a restrictive lung function defect. Chest radiographs showed bilateral pleural fibrosis, with small amounts of fluid in some cases. Soon after bromocriptine was withdrawn, the patients improved clinically, and the laboratory values returned to normal. However, in most cases, pleural fibrosis and a restrictive lung function defect persisted to some extent. In conclusion, in patients who develop pleuropulmonary fibrosis whilst being treated with bromocriptine, former exposure to asbestos should be investigated. Conversely, when pleural changes develop in a patient on bromocriptine and with prior exposure to asbestos, the possible causative role of the drug should be discussed. Special follow-up may be indicated when bromocriptine is planned in a patient with previous asbestos exposure, and if symptoms or signs of pleural fibrosis develop, bromocriptine withdrawal should be considered.
700a Lee, J4 aut
700a Blomkvist, A4 aut
700a Rask-Andersen, Annau Uppsala universitet,Arbets- och miljömedicin4 aut0 (Swepub:uu)annaraan
700a Uddenfeldt, M4 aut
700a Koyi, Hemin4 aut
700a Rasmussen, Eu Uppsala universitet,Arbets- och miljömedicin4 aut
710a Karolinska Institutetb Arbets- och miljömedicin4 org
773t European Respiratory Journald : European Respiratory Society (ERS)g 10:12, s. 2711-2715q 10:12<2711-2715x 0903-1936x 1399-3003
856u http://erj.ersjournals.com/content/10/12/2711.full.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-55174
8564 8u https://doi.org/10.1183/09031936.97.10122711
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1955275

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view